scPharmaceuticals (SCPH): Net earnings per share growth forecast for next year
The US pharmaceutical sector provides businesses with protection against external risks. scPharmaceuticals Inc. is implementing home-based diuretic treatment, thereby reducing costs for insurers. Current success is based on the scaling of Furoscix and insurance coverage. The trend of consensus earnings per share estimates reflects analyst expectations, where 74.40 shows the real-time valuation of this parameter.
scPharmaceuticals, Inc. (SCPH) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Debt to Equity scPharmaceuticals Inc.|SCPH - Long-Term Liabilities to Equity|Short-Term Debt to Capital scpharmaceuticals.com|SCPH - Aggregate Debt Obligations|Debts to Book Capitalization scPharmaceuticals Inc.|SCPH - Company Long-Term Debts|Company Short-Term Debt scPharmaceuticals|Quick Liquidity scpharmaceuticals.com
- net income and valuation ratios data:
SCPH - Net Income|Projected Future Earnings scPharmaceuticals Inc.|SCPH - P/E Multiple|Forward P/E Multiple scpharmaceuticals.com|SCPH - Price/Earnings to Growth Multiple|EV/EBITDA Multiple scPharmaceuticals|SCPH - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months scPharmaceuticals|SCPH - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months scpharmaceuticals.com|SCPH - Net earnings per one share growth for the current year|Earnings growth forecast for next year scPharmaceuticals Inc.
- revenue and sales details:
Fundamental company valuation:scpharmaceuticals.com, SCPH
Strategic alliances of scPharmaceuticals Inc. (SCPH) in cardiology and the implementation of the Furoscix pump optimize hospitalization costs, creating a foundation for revenue growth. The eps_nexty_co metric measures the percentage change in expected earnings per share for the next year relative to current values. Investors utilize this consensus forecast to assess future capitalization and business scaling rates. This trend in expectations is clearly reflected in the forward-looking eps n+1 growth indicator.
Main competitors
Net earnings per share growth forecast for next year Haleon plc|Expected net earnings per share growth next year kenvue.com KVUE|Net earnings per share growth forecast for next year Verona Pharma (VRNA)|MENS (Jyong Biotech Limited) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand Pharma LGND|Earnings growth forecast for next year Amneal Corp AMRX|Perrigo Company PLC - Earnings growth forecast for next year|ALVO: Net earnings per share growth forecast for next year|liquidia.com (LQDA) - Net earnings per share growth forecast for next year|GLPG (Galapagos) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year ANIP|Projected earnings per share growth rate for next year MNKD (Afrezza)|Earnings growth forecast for next year AMPH|PCRX (Pacira BioSciences) - Expected earnings per share trend next year|Earnings growth forecast for next year SPRY (ARS Pharmaceuticals, Inc.)|Theravance Biopharma, Inc. - Net earnings per share growth forecast for next year|Aquestive Corp - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year tectonictx.com TECX|TNXP: Earnings growth forecast for next year|Projected earnings per share growth rate for next year SXTC|Expected earnings per share growth for next year EPRX|BioHarvest (BHST) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year EXOZ|Earnings growth forecast for next year Oramed (ORMP)|Entera Bio Ltd. - Expected earnings per share growth for next year|ipatherapeutics.com (HYFT) - Expected net earnings per share growth next year|ABVC - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year CPIX|QNTM: Earnings growth forecast for next year|FGEN - Consensus forecast of earnings per share growth for next year|TELO (Telomir Pharmaceuticals Corp) - Earnings growth forecast for next year|RANI (Rani Therapeutics) - Projected earnings per share increase next year|Net earnings per share growth forecast for next year Synergy CHC Corp. (SNYR)|RLYB (Rallybio) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year lexariabioscience.com LEXX|Earnings growth forecast for next year Pulmatrix Corporation PULM|PTHL - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Aptorum Group Ltd APM|LYRA (Lyra Therapeutics) - Expected earnings per share growth for next year|IBO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year TNF Pharmaceuticals, Inc.|Expected earnings per share growth for next year cbdMD, Inc. (YCBD)|Net earnings per share growth forecast for next year PainReform Limited (PRFX)|Expected earnings per share growth for next year Altamira Therapeutics Ltd CYTO|Earnings growth forecast for next year LIPO (lipella.com)|Expected earnings per share trend next year OPTN|PIRS - Net earnings per share growth forecast for next year|Procaps Group Corp (PROC) - Expected earnings per share growth for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year QLI (Qilian International)|Expected earnings per share growth for next year SLRN|TFF Pharmaceuticals, Inc. - Net earnings per share change forecast for next year
